Desferal Package Insert

CYTOMEGALOVIRUS IMMUNE GLOBULIN CSL Behring WARNINGS Cytogam
CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) Cytogam ® Liquid Formulation Solvent Detergent Treated DESCRIPTION Cytogam ®, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV), is an immunoglobulin G (IgG) containing a standardized amount of antibody to Cytomegalov irus (CMV). ... View Doc

HIGHLIGHTS OF PRESCRIBING INFORMATION Hypercorticism And ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DULERA safely and effectively. ... View Full Source

Baxter Elastomeric Pumps - CAPCA
*Please refer to Package Insert or the ‘Consider These 5 Conditions’ section of this booklet, as some environmental factors can affect the accuracy of the above flow rate parameters. Intermates: • Offer duration infusion times from 30 minutes to 5 hours. • Designed for ambulatory infusion of: Antibiotic & Antiviral medications. ... Access Content

DESCRIPTION - Novartis US
Desferal® deferoxamine mesylate for injection USP Vials Rx only Prescribing Information DESCRIPTION Desferal, deferoxamine mesylate USP, is an iron-chelating agent, available in vials for intramuscular, subcutaneous, and intravenous administration. Desferal is supplied as vials containing 500 mg of ... Read Content

SPECIALTY GUIDELINE MANAGEMENT
DESFERAL (deferoxamine) Deferoxamine mesylate (generic) POLICY . A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. FDA-Approved Indications ... Read Here

KMHP/AMHP PRIOR AUTHORIZATION CRITERIA - MDwise
1. Manufacturer package insert for Desferal (deferoxamine mesylate) injection, Novartis, September 2010. Revision/Review Date: MAC 9/2010 Associated Policy: Prior Authorization of Medications 236.200 NOTE: Clinical reviewer must override criteria when, in his/her professional judgment, the requested item is medically necessary. ... Document Retrieval

STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN ...
STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES Patient has failed or has had an inadequate response to Desferal (deferoxamine) and Exjade (deferasirox) as defined by serum ferritin greater than 2,500mcg/L before 1. Ferriprox (package insert). Rockville, MD: ApoPharma USA ... Retrieve Document

SPECIALTY GUIDELINE MANAGEMENT - Harvardpilgrim.org
DESFERAL (deferoxamine) Deferoxamine mesylate (generic) POLICY . I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications ... Retrieve Full Source

HIGHLIGHTS OF PRESCRIBING INFORMATION
2 dosage and administration 2.1 2.2 4 contraindications 5 warnings and precautions 5.2 5.3 5.6 6 adverse reactions 7 drug interactions highlights of prescribing information ... Access Full Source

Reference ID: 4196675 - BMS
5.4 Vasculitic Toxicities Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. ... Retrieve Doc

Approval Criteria Department Of Pharmacy Services
Approval Criteria Department of Pharmacy Services Generic Name: deferoxamine Brand Name: Desferal® Medication Class: Chelating agents FDA Approved Uses Acute iron intoxication: for adjunct treatment of acute iron intoxication. Chronic iron overload: for the treatment of chronic iron overload due to transfusion-dependent anemia. ... Get Doc

Clinical Policy: Deferoxamine (Desferal) - Envolve Health
1. Desferal [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2011. Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally ... Retrieve Full Source

KAL964 Elastomeric Clinician Bro En 8.5x11 V7r2FIN
*Please refer to Package Insert or the ‘Consider These 5 Conditions’ section of this booklet, as some environmental factors can affect the accuracy of the above flow rate parameters. Small Volume (SV) Devices: Small Elastomeric Reservoirs that can hold 105 to 130 mL of solution. ... Retrieve Content

HIGHLIGHTS OF PRESCRIBING INFORMATION Infusion-related ...
2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Invasive Aspergillosis CRESEMBA® is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis [see Clinical Studies (14.1) and Clinical Pharmacology (12.4)]. 1.2 Invasive Mucormycosis ... Access Full Source

Desferal Deferoxamine Mesylate For Injection USP Prescribing ...
Desferal, deferoxamine mesylate USP, is an iron-chelating agent, available in vials for intramuscular, subcutaneous, and intravenous administration. Desferal is supplied as vials ... Fetch Content

Line Of Business: Non-Medicare
Package Insert: Desferal ®. Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2011. 5. A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease ... Fetch This Document

Deferoxamine Mesylate For Injection, USP
Package Insert Rx only Deferoxamine Mesylate for Injection, USP. Hypersensitivity Reactions and Systemic Allergic Reactions Generalized rash, urticaria, anaphylactic reaction with or without shock, angioedema. Body as a Whole ... Visit Document

DESFERAL 0.5 G - Apteki-israel.info
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986 The dispensing of this medicine requires a doctor’s prescription Read this package insert carefully in its entirety before using this medicine DESFERAL® 0.5 g Powder for solution for intramuscular (I.M.) injection. ... Access Document